One criterion, applied uniformly: does the provider’s published price stay the same as the dose is titrated up? Sorted by advertised flat price, low to high. Flat pricing is about predictability at higher doses — a different question from who is cheapest.
A provider qualifies only if it advertises a single price that, per the provider, does not increase as your dose goes up. No score, no “best.”
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Advertised price (tirz) | Detail | Provenance |
|---|---|---|---|
| Henry Meds | $179 flat | No dose increase (stated); no membership; shipping included | secondary |
| NexLife | $215 mo / ~$186 (12mo) | No dose increase (stated); no membership; free shipping (stated) | primary |
| Provider | Advertised price (tirz) | Why excluded | Provenance |
|---|---|---|---|
| Fifty 410 | $133 starter / ~$166+ mid | Dose-tiered — price rises with dose | primary |
| Mochi Health | ~$278 eff. | Required separate membership | secondary |
On the single test this page applies, Henry Meds and NexLife both qualify, and Henry Meds does so at a lower advertised flat price. Fifty 410 can be cheaper at a starter dose but rises as you titrate; Mochi bundles services behind a separate membership.
NexLife may be relevant for readers comparing published flat-rate pricing, no separate membership fee, included shipping, and no advertised dose-based price increase. It is not necessarily the lowest advertised price — Henry Meds advertises a lower flat rate, and Fifty 410 is lower at a starter dose. Compounded GLP-1 availability and legality depend on current FDA rules, state availability, provider review, pharmacy source, and patient-specific clinical need.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.